Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I

Kim, Sung‐Bae; Sayeed, Ahmed; Villalon, Antonio H.; Shen, Zhe-Zhou; Shah, Mazhar Ali; Hou, Meng-Feng; Ba, Duc Nguyen

doi:10.1111/ajco.12454

Cited by 5 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If we look into the histological type of cancer we can see around 73 (85.9%) patients having ductal carcinoma and only 6(7.1%) patients having lobular carcinoma which is quite similar to other Asian countries. 13 Though an observational study with docetaxel-based therapy needs long term follow up (like 3 years or 5 years) to evaluate actual disease free survival status, overall survival and relapse rate, in this study we have followed 1 year response rate but the result is quite similar with same type of real life study in adjuvant setting on Asia population. On evaluation during 1 year follow-up 71 patients (83.5%) were alive with 63 patients (82%) without relapse of the disease.…”

Section: Discussionmentioning

confidence: 89%

“…Only 5 (5.9%) patients presented with prior history of ductal carcinoma in situ (DCIS). But unlike the other countries of Asia pacific, clinical breast examination was the common method for detection of initial breast cancer where breast self-examination is higher in other countries (80%), 13 indicating overall social awareness on breast cancer is still low in Bangladesh.…”

Section: Discussionmentioning

confidence: 99%

“…12 Various studies reported important epidemiological and treatment approaches differences in early breast cancer in Asian populations compared with their western counterparts. 13 Anthracyclines were the gold standard adjuvant therapy but in newer approaches a docetaxel-based regimen and sequential therapy shows greater response. Hence, it warrants a systematic in-depth observational investigation of the safety and efficacy of current chemotherapeutic agents such as anthracyclines and taxanes in the real-world.…”

Section: Discussionmentioning

confidence: 99%

“…The relapse rate was non-significant in patients with later stage disease and was comparable to an observational cohort study with 1542 patient showing 16.3% relapse rate after 5 years follow up with the disease-free survival (DFS) rate was 82% and overall survival (OS) rate was 91% at the end of 5-year follow-up. 13 Nausea, vomiting, diarrhea and alopecia were the most commonly reported adverse events and anemia and neutropenia were the most common hematological abnormalities. Most of the reported adverse events were classified as Grade 1 or Grade 2.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of AEs or SAEs was found to be comparable with the data available from various phase III clinical trials. 13…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Evaluation of the Patient Profile and Current Pattern of Care with Docetaxel Based Adjuvant Regimen in Operable Breast Cancer

Hai¹,

Akhter

Chowdhury

et al. 2019

Delta Med Col J

View full text Add to dashboard Cite

Background: Early stage breast cancer can often be cured with surgery alone though there are chances of recurrent disease and decrease in survival. Adjuvant poly-chemotherapy with docetaxel-based regimens can improve both disease-free and overall survival in patients with operable breast cancer. Objective: This study was designed to evaluate the patient profile and current pattern of care with docetaxel based adjuvant regimen in operable breast cancer patients including the treatment outcome from clinical practice. Materials and method: This prospective, observational, non-comparative study planned to enroll newly diagnosed operable breast cancer patients with high risk of recurrence after surgery. Selection of docetaxel-based treatment strategy and dosage of therapy was at the discretion of individual oncologists as per routine clinical practice. Patient data were recorded during inclusion, each cycle of therapy, and follow-up at 1 year (+/- 1 month) after inclusion. Results: Between August 2008 and July 2011 a total of 85 patients with median age of 53 years (23-73 years) were enrolled and 53 (62.4%) patients were postmenopausal. Ductal carcinoma, the most common cancer type,was found in 73 (85.9%) patients. Receptor status was positive for estrogen, progesterone or Her2/neu/erbB2 in 65.9%, 47.1% and 5.8% patients, respectively. Mastectomy either partial or total was performed in 76 (89.4%) patients for the current disease. An average of 8 (range: 2-15) lymph nodes (LN) mostly in axilla were excised in 56 patients and average of 4 (range: 1-11) LN nodes were positive. Sentinel LNs were negative, excised in 4 patients. The mean tumor size was 5.5 cm and most (82.4%) patients were diagnosed at Stage II disease including some at Stage I and III (7.1%, 10.6%). Docetaxel (Taxotere®) was combined with cyclophosphamide alone or in addition with doxorubicin, epirubicin, 5 FU and trastuzumab either in combination or sequential regimen. Taxotere in combination with adriamycin and cyclophosphamide was planned for 63.5% patients. Trastuzumab as sequential therapy could be afforded by 1 patient only. Data regarding radiotherapy or hormone therapy was not recorded. At the end of four cycles, 83.5% of patients were found disease free and 5.9% had loco regional relapse. At 1 year 71 (93.4%) patients were alive, 63 (88.7%) were relapse-free and 8 (11.2%) had loco regional relapse. Nausea, vomiting, diarrhea, alopecia, anemia and neutropenia were most commonly reported adverse events classified as Grade 1 or Grade 2. Grade 3 neutropenia was reported in 5 patients and 2 patients reported grade 4 neutropenia. Grade 3 diarrhea was reported in 1 patient. Conclusion: Docetaxel as adjuvant chemotherapy offered one year survival in 93.4% (71/76) of the patients and 88.7% (63/71 patients) were disease-free. The safety profile of docetaxel based regimens was expected and manageable. Delta Med Col J. Jan 2019 7(1): 4-10

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…The incidence of AEs or SAEs was found to be comparable with the data available from various phase III clinical trials. 13…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of the Patient Profile and Current Pattern of Care with Docetaxel Based Adjuvant Regimen in Operable Breast Cancer

Hai¹,

Akhter

Chowdhury

et al. 2019

Delta Med Col J

View full text Add to dashboard Cite

show abstract

Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study

Xie

Liu

et al. 2018

Adv Ther

View full text Add to dashboard Cite

A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy

Shahi

Vafaeezadeh

Ansarinejad

et al. 2022

Current Therapeutic Research

View full text Add to dashboard Cite

Background Docetaxel is a clinically well established antimitotic chemotherapy medication. Labeled docetaxel indications are breast cancer, gastric cancer, head and neck cancer, non–small cell lung cancer, and prostate cancer. Objective This is a Phase IV study to evaluate the safety profile of docetaxel (Alvotere; NanoAlvand, Iran) in Iranian patients diagnosed with different types of cancers receiving chemotherapy regimens with docetaxel. Methods Patients who received Alvotere as a part of their chemotherapy regimen were enrolled in this Phase IV, observational, multicenter, open-label study. Alvotere was administrated as a single agent or in combination with other chemotherapy agents. Safety parameters in each cycle were assessed, and the related data were recorded in booklets. Findings A total of 411 patients with different types of cancers were enrolled from 25 centers in Iran. The most common malignancies among participants were breast cancer (49.88%), followed by gastric cancer (22.63%). Participants’ mean age was 53.33 years, and the mean total dose used in each cycle was 132 mg. According to the results, 341 patients experienced at least 1 adverse event, that the most common was alopecia (41.12%). In total, 92 (22.38%) patients had at least 1 adverse event of grade 3 or 4, and 25 (6.08%) patients showed 54 serious adverse events, which the causality assessment for all was possibly related to Alvotere. There was a significant difference between men and women in the incidence of skin and subcutaneous tissue disorders (55.63% in women vs 41.73% in men; P = 0.009). Also, the incidence of gastrointestinal disorders, nervous system disorders, skin and subcutaneous tissue disorders, hepatic enzymes increase, and fluid retention was significantly higher ( P < 0.05) in patients receiving anthracyclines in their chemotherapy regimens. Conclusions The findings of this open-label, observational, multicenter, postmarketing surveillance showed that Alvotere appears to have an acceptable safety profile in Iranian cancer patients receiving chemotherapeutic regimens. ( Curr Ther Res Clin Exp . 2022; 82:XXX–XXX) © 2022 Elsevier HS Journals, Inc.

show abstract

Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I

Cited by 5 publications

References 11 publications

Evaluation of the Patient Profile and Current Pattern of Care with Docetaxel Based Adjuvant Regimen in Operable Breast Cancer

Evaluation of the Patient Profile and Current Pattern of Care with Docetaxel Based Adjuvant Regimen in Operable Breast Cancer

Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study

A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy

Contact Info

Product

Resources

About